What Sustained Therapeutics does

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release drug delivery platform based on a soft polymer gel that enables localized, long-acting drug release from a single injection. The platform's core technology allows tunable drug release over days, weeks, or months without requiring additional solvents, with a biocompatible formulation designed to minimize systemic side effects. The company was founded as a spin-off from the University of British Columbia and the Vancouver Prostate Centre and is headquartered at the Jack Bell Research Centre in Vancouver, Canada.

The company is advancing three pipeline candidates: ST-01, a sustained-release lidocaine formulation for chronic scrotal content pain (Phase 2 positive readout in January 2026, with 67% treatment response and 83% clinical response at the 70 mg/mL dose versus control); ST-02, a sustained-release gemcitabine formulation for upper tract urothelial carcinoma delivered via ureteric catheter (Phase II/III underway, targeting orphan indication); and ST-04, a mucoadhesive alprostadil formulation for erectile dysfunction (Phase II planned Q1 2026). The platform's versatility supports potential application across pain, oncology, and sexual health indications.

Sustained Therapeutics is pre-revenue and generates no product sales. The business model is structured around eventual pharmaceutical product commercialization upon regulatory approval, with clinical trials conducted through investigator-sponsored and company-sponsored protocols at multiple Canadian academic medical centers. The company has secured Health Canada regulatory clearances for its trials and is pursuing US regulatory approval for Phase 3 development of ST-01. Its go-to-market strategy targets urologists and pain specialists directly through clinical trial site relationships and conference presentations, including the American Urological Association Annual Meeting.

Name

Sustained Therapeutics

Legal name

Sustained Therapeutics Inc.

Website

https://sustainedtherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a patented sustained-release soft polymer gel platform for localized, long-acting drug delivery. It is advancing pipeline candidates ST-01 for chronic pain, ST-02 for urothelial carcinoma, and ST-04 for erectile dysfunction.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Sustained-release pharmaceuticals
• Non-opioid pain therapy
• Drug delivery platform
• Clinical-stage biopharmaceutical
• Localized injectable therapeutics

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company developing proprietary sustained-release drug products. Revenue expected from product sales upon regulatory approval. Pipeline includes ST-01 for chronic pain, ST-02 for upper tract urothelial carcinoma, and ST-04 for erectile dysfunction.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Sustained Therapeutics is a clinical-stage pharmaceutical company developing a proprietary soft polymer gel drug delivery platform that enables sustained-release, localized injectable therapeutics. The company is advancing a pipeline of candidates targeting non-opioid pain management, urologic oncology, and sexual dysfunction, with three lead programs (ST-01, ST-02, ST-04) currently in or nearing Phase II clinical trials. Products are designed to deliver drug payloads over days, weeks, or months from a single injection at the targeted body site.

Product overview

Sustained Therapeutics is a clinical-stage pharmaceutical company with a patented sustained-release drug delivery platform technology. The company is developing a pipeline of therapeutic candidates including: ST-01 (sustained-release lidocaine for chronic scrotal content pain and postoperative pain), ST-02 (sustained-release gemcitabine for upper tract urothelial carcinoma), and ST-04 (alprostadil for erectile dysfunction). The proprietary platform consists of a soft polymer gel that enables localized, long-lasting drug delivery via injection, designed to release medications over days, weeks, or months depending on formulation.

Differentiator

Problem solved

Functional benefit

Brands

• ST-01: Sustained-release lidocaine formulation for the treatment of acute and chronic pain
• ST-02
• ST-04

Products and services

• ST-01 ST-01 is a sustained-release lidocaine formulation designed for localized, non-opioid treatment of acute and chronic pain. The proprietary soft polymer gel delivers lidocaine slowly over approximately 28 days from a single injection, providing sustained pain relief without opioid dependency risks. It is intended for office-based administration by physicians without specialized training and targets indications including chronic scrotal content pain and postoperative pain.
• ST-02 ST-02 is a sustained-release gemcitabine formulation for the treatment of upper tract urothelial carcinoma (UTUC), a urologic oncology indication. It is delivered via ureteric catheter directly to the renal pelvis, where the formulation coats tissue and delivers chemotherapy over an extended period directly at the cancer site. The program may qualify for orphan drug designation, potentially granting seven years of market exclusivity, tax credits, and fee exemptions.
• ST-04 ST-04 is a locally delivered erectile dysfunction therapy using a patent-protected mucoadhesive formulation containing alprostadil. It is delivered via transurethral absorption, designed to provide excellent local pharmacokinetics while avoiding systemic delivery, with the intent of fewer side effects compared with current ED therapies.

Quantifiable outcome

• 67% treatment response (≥2-point pain reduction) at 70 mg/mL dose vs 26% control (p=0.01)
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Vancouver Prostate CentrecoreStrategic or Co-development Partner · 16 November 2023Vancouver Prostate Centre (VPC), a National Centre of Excellence and designated Centre of Excellence for Commercialization and Research, is conducting the investigator-sponsored trial (IST) for ST-02. VPC has received Health Canada approval to conduct the study for ablation of urothelial carcinomas in the upper urinary tract. The partnership leverages VPC's clinical trials facility and world-class translational research program under the same roof.
• University of British ColumbiacoreStrategic or Co-development PartnerSustained Therapeutics was founded as a spin-off from the University of British Columbia and the Vancouver Prostate Centre. The company was founded by leading urologists and scientists from UBC including Dr. Martin Gleave, Distinguished Professor and Chair of the Department of Urologic Sciences.
• Dr. Ryan K FlanniganminorOthersDr. Ryan K Flannigan, Associate Professor at UBC and Director of the Male Reproductive and Sexual Medicine Research Program, served as lead investigator for the Phase 2 study of ST-01 in chronic scrotal content pain, presenting results at AUA 2026.
• Dr. Peter BlackminorOthersDr. Peter Black, Senior Research Scientist at Vancouver Prostate Centre, is the lead investigator for the Phase II/III clinical trial of ST-02 for Upper Tract Urothelial Carcinoma.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Veru Inc. Veru is a urology-focused specialty pharma addressing prostate cancer and sexual health. Comparable therapeutic-area focus to Sustained Therapeutics' urology pipeline (ST-01 chronic scrotal pain, ST-02 UTUC, ST-04 erectile dysfunction).

Direct peers

• Heron Therapeutics: Heron develops sustained-release injectable therapeutics for postoperative pain and oncology supportive care using its proprietary polymer-based delivery platforms. Its Zynrelef (bupivacaine/meloxicam) and oncology-support franchises directly parallel Sustained Therapeutics' ST-01 and ST-02.
• DURECT Corporation: DURECT is a specialty pharma company built around sustained-release drug delivery technologies (e.g., POSIMIR, SABER platform) — comparable to Sustained Therapeutics' polymer-gel platform approach. Both companies pursue formulation-based improvements to approved APIs across pain and other indications.
• Pacira BioSciences: Pacira markets Exparel, a sustained-release bupivacaine injectable for postoperative pain — directly comparable to Sustained Therapeutics' ST-01 sustained-release lidocaine strategy. Both target localized, long-acting non-opioid pain control via proprietary injectable depot technology.

Broad incumbents

• Endo Pharmaceuticals: Endo is a broad specialty pharma with established lidocaine (Lidoderm) and pain franchises. Its former CEO Carol Ammon is a Sustained Therapeutics board member, providing a strategic linkage; comparable in therapeutic area focus if not delivery technology.
• Collegium Pharmaceutical: Collegium is a specialty pain pharmaceutical company focused on abuse-deterrent and non-opioid pain therapies. Its commercial franchise in chronic pain overlaps with Sustained Therapeutics' ST-01 strategic positioning, though Collegium is more commercially mature.

Emerging players

• Aquestive Therapeutics: Aquestive is a specialty pharma with proprietary drug delivery platforms (Philmistry, Aqstry) for CNS and allergy therapeutics. Comparable as a platform-based reformulation company seeking to improve approved molecules via novel delivery technologies.
• Trevena Inc. Trevena is a clinical-stage pain pharma focused on novel opioid and non-opioid analgesic mechanisms. While technology differs, it competes in the same chronic/acute pain treatment paradigm Sustained Therapeutics targets with ST-01.
• Innocoll Pharmaceuticals: Innocoll develops biodegradable, sustained-release collagen-based matrices for local drug delivery, including postsurgical pain and surgical site infections. Its local sustained-release approach directly parallels Sustained Therapeutics' ST-01 concept.
• Aclaris Therapeutics: Aclaris is a clinical-stage specialty pharma developing novel therapeutics in immunology and oncology. Comparable as a small-cap clinical-stage pharma pursuing reformulation and novel delivery approaches in specialty indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sustained-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sustained Therapeutics